['* THE INTERACTION BETWEEN SUSTIVA AND THE DRUG WAS EVALUATED IN A CLINICAL STUDY. ALL OTHER DRUG INTERACTIONS SHOWN ARE PREDICTED.', 'THIS TABLE IS NOT ALL-INCLUSIVE.', 'HIV ANTIVIRAL AGENTS', 'PROTEASE INHIBITOR: FOSAMPRENAVIR CALCIUM', '\xe2\x86\x93\xc2\xa0AMPRENAVIR', 'FOSAMPRENAVIR(UNBOOSTED): APPROPRIATE DOSES OF THE COMBINATIONS WITH RESPECT TO SAFETYAND EFFICACY HAVE NOT BEEN ESTABLISHED. FOSAMPRENAVIR/RITONAVIR:AN ADDITIONAL 100 MG/DAY (300 MG TOTAL) OF RITONAVIR IS RECOMMENDED WHEN SUSTIVAIS ADMINISTERED WITH FOSAMPRENAVIR/RITONAVIR ONCE DAILY. NO CHANGE IN THERITONAVIR DOSE IS REQUIRED WHEN SUSTIVA IS ADMINISTERED WITH FOSAMPRENAVIRPLUS RITONAVIR TWICE DAILY.', 'PROTEASE INHIBITOR: ATAZANAVIR SULFATE', '\xe2\x86\x93\xc2\xa0ATAZANAVIR *', 'TREATMENT-NAIVE PATIENTS: WHEN COADMINISTERED WITH SUSTIVA, THE RECOMMENDED DOSE OF ATAZANAVIR IS 400 MG WITH RITONAVIR 100 MG (TOGETHER ONCE DAILY WITH FOOD) AND SUSTIVA 600 MG (ONCE DAILY ON AN EMPTY STOMACH, PREFERABLY AT BEDTIME). TREATMENT-EXPERIENCED PATIENTS: COADMINISTRATION OF SUSTIVA AND ATAZANAVIR IS NOT RECOMMENDED.', 'PROTEASE INHIBITOR: INDINAVIR', '\xe2\x86\x93\xc2\xa0INDINAVIR *', 'THE OPTIMAL DOSEOF INDINAVIR, WHEN GIVEN IN COMBINATION WITH SUSTIVA, IS NOT KNOWN. INCREASINGTHE INDINAVIR DOSE TO 1000\xc2\xa0MG EVERY 8 HOURS DOES NOT COMPENSATE FOR THE INCREASEDINDINAVIR METABOLISM DUE TO SUSTIVA. WHEN INDINAVIR AT AN INCREASED DOSE (1000\xc2\xa0MGEVERY 8 HOURS) WAS GIVEN WITH SUSTIVA (600\xc2\xa0MG ONCE DAILY), THE INDINAVIR AUCAND C MIN WERE DECREASED ON AVERAGE BY 33-46% AND 39-57%,RESPECTIVELY, COMPARED TO WHEN INDINAVIR (800\xc2\xa0MG EVERY 8 HOURS) WAS GIVENALONE.', 'PROTEASE INHIBITOR: LOPINAVIR/RITONAVIR', '\xe2\x86\x93\xc2\xa0LOPINAVIR *', 'LOPINAVIR/RITONAVIRTABLETS SHOULD NOT BE ADMINISTERED ONCE DAILY IN COMBINATION WITH SUSTIVA.IN ANTIRETROVIRAL-NAIVE PATIENTS, LOPINAVIR/RITONAVIR TABLETS CAN BE USEDTWICE DAILY IN COMBINATION WITH SUSTIVA WITH NO DOSE ADJUSTMENT. A DOSE INCREASEOF LOPINAVIR/RITONAVIR TABLETS TO 600/150\xc2\xa0MG (3\xc2\xa0TABLETS) TWICE DAILY MAY BECONSIDERED WHEN USED IN COMBINATION WITH SUSTIVA IN TREATMENT-EXPERIENCEDPATIENTS WHERE DECREASED SUSCEPTIBILITY TO LOPINAVIR IS CLINICALLY SUSPECTED(BY TREATMENT HISTORY OR LABORATORY EVIDENCE). A DOSE INCREASE OF LOPINAVIR/RITONAVIRORAL SOLUTION TO 533/133\xc2\xa0MG (6.5\xc2\xa0ML) TWICE DAILY TAKEN WITH FOOD IS RECOMMENDEDWHEN USED IN COMBINATION WITH SUSTIVA.', 'PROTEASE INHIBITOR: RITONAVIR', '\xe2\x86\x91\xc2\xa0RITONAVIR * \xe2\x86\x91\xc2\xa0EFAVIRENZ *', 'WHEN RITONAVIR500 MG Q12H WAS COADMINISTERED WITH SUSTIVA 600 MG ONCE DAILY, THE COMBINATIONWAS ASSOCIATED WITH A HIGHER FREQUENCY OF ADVERSE CLINICAL EXPERIENCES (EG,DIZZINESS, NAUSEA, PARESTHESIA) AND LABORATORY ABNORMALITIES (ELEVATED LIVERENZYMES). MONITORING OF LIVER ENZYMES IS RECOMMENDED WHEN SUSTIVA IS USEDIN COMBINATION WITH RITONAVIR.', 'PROTEASE INHIBITOR: SAQUINAVIR', '\xe2\x86\x93\xc2\xa0SAQUINAVIR *', 'SHOULD NOT BE USED AS SOLE PROTEASE INHIBITOR IN COMBINATION WITH SUSTIVA.', 'NNRTI: OTHER NNRTIS', '\xe2\x86\x91\xc2\xa0OR \xe2\x86\x93\xc2\xa0EFAVIRENZ AND/OR NNRTI', 'COMBINING TWO NNRTIS HAS NOT BEEN SHOWN TO BE BENEFICIAL. SUSTIVA SHOULD NOT BE COADMINISTERED WITH OTHER NNRTIS.', 'CCR5 CO-RECEPTOR ANTAGONIST: MARAVIROC', '\xe2\x86\x93\xc2\xa0MARAVIROC *', 'REFER TO THE FULL PRESCRIBING INFORMATION FOR MARAVIROC FOR GUIDANCE ON COADMINISTRATION WITH EFAVIRENZ.', 'INTEGRASE STRAND TRANSFER INHIBITOR: RALTEGRAVIR', '\xe2\x86\x93\xc2\xa0RALTEGRAVIR *', 'SUSTIVA REDUCES PLASMA CONCENTRATIONS OF RALTEGRAVIR. THE CLINICAL SIGNIFICANCE OF THIS INTERACTION HAS NOT BEEN DIRECTLY ASSESSED.', 'HEPATITIS C ANTIVIRAL AGENTS', 'PROTEASE INHIBITOR: BOCEPREVIR', '\xe2\x86\x93\xc2\xa0BOCEPREVIR *', 'PLASMA TROUGH CONCENTRATIONS OF BOCEPREVIR WERE DECREASED WHEN BOCEPREVIR WAS COADMINISTERED WITH SUSTIVA, WHICH MAY RESULT IN LOSS OF THERAPEUTIC EFFECT. THE COMBINATION SHOULD BE AVOIDED.', 'PROTEASE INHIBITOR: TELAPREVIR', '\xe2\x86\x93\xc2\xa0TELAPREVIR * \xe2\x86\x93\xc2\xa0EFAVIRENZ *', 'CONCOMITANT ADMINISTRATION OF TELAPREVIR AND SUSTIVA RESULTED IN REDUCED STEADY-STATE EXPOSURES TO TELAPREVIR AND EFAVIRENZ.', 'OTHER AGENTS', 'ANTICOAGULANT: WARFARIN', '\xe2\x86\x91\xc2\xa0OR\xc2\xa0\xe2\x86\x93\xc2\xa0WARFARIN', 'PLASMA CONCENTRATIONSAND EFFECTS POTENTIALLY INCREASED OR DECREASED BY SUSTIVA.', 'ANTICONVULSANTS: CARBAMAZEPINE', '\xe2\x86\x93\xc2\xa0CARBAMAZEPINE * \xe2\x86\x93\xc2\xa0EFAVIRENZ *', 'THERE ARE INSUFFICIENTDATA TO MAKE A DOSE RECOMMENDATION FOR EFAVIRENZ. ALTERNATIVE ANTICONVULSANTTREATMENT SHOULD BE USED.', 'PHENYTOIN PHENOBARBITAL', '\xe2\x86\x93\xc2\xa0ANTICONVULSANT \xe2\x86\x93\xc2\xa0EFAVIRENZ', 'POTENTIAL FORREDUCTION IN ANTICONVULSANT AND/OR EFAVIRENZ PLASMA LEVELS; PERIODIC MONITORINGOF ANTICONVULSANT PLASMA LEVELS SHOULD BE CONDUCTED.', 'ANTIDEPRESSANTS: BUPROPION', '\xe2\x86\x93\xc2\xa0BUPROPION *', 'THE EFFECT OF EFAVIRENZ ON BUPROPION EXPOSURE IS THOUGHT TO BE DUE TO THE INDUCTION OF BUPROPION METABOLISM. INCREASES IN BUPROPION DOSAGE SHOULD BE GUIDED BY CLINICAL RESPONSE, BUT THE MAXIMUM RECOMMENDED DOSE OF BUPROPION SHOULD NOT BE EXCEEDED.', 'SERTRALINE', '\xe2\x86\x93\xc2\xa0SERTRALINE *', 'INCREASES IN SERTRALINEDOSAGE SHOULD BE GUIDED BY CLINICAL RESPONSE.', 'ANTIFUNGALS: VORICONAZOLE', '\xe2\x86\x93\xc2\xa0VORICONAZOLE * \xe2\x86\x91\xc2\xa0EFAVIRENZ *', 'SUSTIVA AND VORICONAZOLEMUST NOT BE COADMINISTERED AT STANDARD DOSES. EFAVIRENZ SIGNIFICANTLY DECREASESVORICONAZOLE PLASMA CONCENTRATIONS, AND COADMINISTRATION MAY DECREASE THETHERAPEUTIC EFFECTIVENESS OF VORICONAZOLE. ALSO, VORICONAZOLE SIGNIFICANTLYINCREASES EFAVIRENZ PLASMA CONCENTRATIONS, WHICH MAY INCREASE THE RISK OFSUSTIVA-ASSOCIATED SIDE EFFECTS. WHEN VORICONAZOLE IS COADMINISTERED WITHSUSTIVA, VORICONAZOLE MAINTENANCE DOSE SHOULD BE INCREASED TO 400\xc2\xa0MG EVERY12\xc2\xa0HOURS AND SUSTIVA DOSE SHOULD BE DECREASED TO 300\xc2\xa0MG ONCE DAILY USING THECAPSULE FORMULATION. SUSTIVA TABLETS SHOULD NOT BE BROKEN. [SEE DOSAGEAND ADMINISTRATION (2.1) AND CLINICALPHARMACOLOGY (12.3 , TABLES 8 AND 9) .]', 'ITRACONAZOLE', '\xe2\x86\x93\xc2\xa0ITRACONAZOLE * \xe2\x86\x93\xc2\xa0HYDROXYITRACONAZOLE *', 'SINCE NO DOSE RECOMMENDATIONFOR ITRACONAZOLE CAN BE MADE, ALTERNATIVE ANTIFUNGAL TREATMENT SHOULD BE CONSIDERED.', 'KETOCONAZOLE', '\xe2\x86\x93\xc2\xa0KETOCONAZOLE', 'DRUG INTERACTIONSTUDIES WITH SUSTIVA AND KETOCONAZOLE HAVE NOT BEEN CONDUCTED. SUSTIVA HASTHE POTENTIAL TO DECREASE PLASMA CONCENTRATIONS OF KETOCONAZOLE.', 'POSACONAZOLE', '\xe2\x86\x93\xc2\xa0POSACONAZOLE *', 'AVOID CONCOMITANT USE UNLESS THE BENEFIT OUTWEIGHS THE RISKS.', 'ANTI-INFECTIVE: CLARITHROMYCIN', '\xe2\x86\x93\xc2\xa0CLARITHROMYCIN * \xe2\x86\x91\xc2\xa014-OHMETABOLITE *', 'PLASMA CONCENTRATIONSDECREASED BY SUSTIVA; CLINICAL SIGNIFICANCE UNKNOWN. IN UNINFECTED VOLUNTEERS,46% DEVELOPED RASH WHILE RECEIVING SUSTIVA AND CLARITHROMYCIN. NO DOSE ADJUSTMENTOF SUSTIVA IS RECOMMENDED WHEN GIVEN WITH CLARITHROMYCIN. ALTERNATIVES TOCLARITHROMYCIN, SUCH AS AZITHROMYCIN, SHOULD BE CONSIDERED (SEE OTHER DRUGS , FOLLOWING TABLE). OTHERMACROLIDE ANTIBIOTICS, SUCH AS ERYTHROMYCIN, HAVE NOT BEEN STUDIED IN COMBINATIONWITH SUSTIVA.', 'ANTIMYCOBACTERIALS: RIFABUTIN', '\xe2\x86\x93\xc2\xa0RIFABUTIN *', 'INCREASE DAILY DOSE OF RIFABUTINBY 50%. CONSIDER DOUBLING THE RIFABUTIN DOSE IN REGIMENS WHERE RIFABUTIN ISGIVEN 2 OR 3 TIMES A WEEK.', 'RIFAMPIN', '\xe2\x86\x93\xc2\xa0EFAVIRENZ *', 'IF SUSTIVA IS COADMINISTERED WITH RIFAMPIN TO PATIENTS WEIGHING 50 KG OR MORE, AN INCREASE IN THE DOSE OF SUSTIVA TO 800 MG ONCE DAILY IS RECOMMENDED.', 'CALCIUM CHANNEL BLOCKERS: DILTIAZEM', '\xe2\x86\x93\xc2\xa0DILTIAZEM * \xe2\x86\x93\xc2\xa0DESACETYL DILTIAZEM * \xe2\x86\x93\xc2\xa0N-MONODESMETHYL DILTIAZEM *', 'DILTIAZEM DOSE ADJUSTMENTS SHOULDBE GUIDED BY CLINICAL RESPONSE (REFER TO THE FULL PRESCRIBING INFORMATIONFOR DILTIAZEM). NO DOSE ADJUSTMENT OF EFAVIRENZ IS NECESSARY WHEN ADMINISTEREDWITH DILTIAZEM.', 'OTHERS (EG, FELODIPINE,NICARDIPINE, NIFEDIPINE, VERAPAMIL)', '\xe2\x86\x93\xc2\xa0CALCIUMCHANNEL BLOCKER', 'NO DATA ARE AVAILABLEON THE POTENTIAL INTERACTIONS OF EFAVIRENZ WITH OTHER CALCIUM CHANNEL BLOCKERSTHAT ARE SUBSTRATES OF CYP3A. THE POTENTIAL EXISTS FOR REDUCTION IN PLASMACONCENTRATIONS OF THE CALCIUM CHANNEL BLOCKER. DOSE ADJUSTMENTS SHOULD BEGUIDED BY CLINICAL RESPONSE (REFER TO THE FULL PRESCRIBING INFORMATIONFOR THE CALCIUM CHANNEL BLOCKER).', 'HMG-COA REDUCTASEINHIBITORS: ATORVASTATIN PRAVASTATIN SIMVASTATIN', '\xe2\x86\x93\xc2\xa0ATORVASTATIN * \xe2\x86\x93\xc2\xa0PRAVASTATIN * \xe2\x86\x93\xc2\xa0SIMVASTATIN *', 'PLASMA CONCENTRATIONSOF ATORVASTATIN, PRAVASTATIN, AND SIMVASTATIN DECREASED. CONSULT THE FULLPRESCRIBING INFORMATION FOR THE HMG-COA REDUCTASE INHIBITOR FOR GUIDANCE ONINDIVIDUALIZING THE DOSE.', 'HORMONAL CONTRACEPTIVES: ORAL ETHINYLESTRADIOL/ NORGESTIMATE', '\xe2\x86\x93\xc2\xa0ACTIVE METABOLITES OF NORGESTIMATE *', 'A RELIABLE METHOD OF BARRIER CONTRACEPTION MUST BE USED IN ADDITION TO HORMONAL CONTRACEPTIVES. EFAVIRENZ HAD NO EFFECT ON ETHINYL ESTRADIOL CONCENTRATIONS, BUT PROGESTIN LEVELS (NORELGESTROMIN AND LEVONORGESTREL) WERE MARKEDLY DECREASED. NO EFFECT OF ETHINYL ESTRADIOL/NORGESTIMATE ON EFAVIRENZ PLASMA CONCENTRATIONS WAS OBSERVED.', 'IMPLANT ETONOGESTREL', '\xe2\x86\x93\xc2\xa0ETONOGESTREL', 'A RELIABLE METHOD OF BARRIER CONTRACEPTION MUST BE USED IN ADDITION TO HORMONAL CONTRACEPTIVES. THE INTERACTION BETWEEN ETONOGESTREL AND EFAVIRENZ HAS NOT BEEN STUDIED. DECREASED EXPOSURE OF ETONOGESTREL MAY BE EXPECTED. THERE HAVE BEEN POSTMARKETING REPORTS OF CONTRACEPTIVE FAILURE WITH ETONOGESTREL IN EFAVIRENZ-EXPOSED PATIENTS.', 'IMMUNOSUPPRESSANTS: CYCLOSPORINE, TACROLIMUS, SIROLIMUS, AND OTHERS METABOLIZED BY CYP3A', '\xe2\x86\x93\xc2\xa0IMMUNOSUPPRESSANT', 'DECREASED EXPOSURE OF THE IMMUNOSUPPRESSANT MAY BE EXPECTED DUE TO CYP3A INDUCTION. THESE IMMUNOSUPPRESSANTS ARE NOT ANTICIPATED TO AFFECT EXPOSURE OF EFAVIRENZ. DOSE ADJUSTMENTS OF THE IMMUNOSUPPRESSANT MAY BE REQUIRED. CLOSE MONITORING OF IMMUNOSUPPRESSANT CONCENTRATIONS FOR AT LEAST 2 WEEKS (UNTIL STABLE CONCENTRATIONS ARE REACHED) IS RECOMMENDED WHEN STARTING OR STOPPING TREATMENT WITH EFAVIRENZ.', 'NARCOTIC ANALGESIC: METHADONE', '\xe2\x86\x93\xc2\xa0METHADONE *', 'COADMINISTRATIONIN HIV-INFECTED INDIVIDUALS WITH A HISTORY OF INJECTION DRUG USE RESULTEDIN DECREASED PLASMA LEVELS OF METHADONE AND SIGNS OF OPIATE WITHDRAWAL. METHADONEDOSE WAS INCREASED BY A MEAN OF 22% TO ALLEVIATE WITHDRAWAL SYMPTOMS. PATIENTSSHOULD BE MONITORED FOR SIGNS OF WITHDRAWAL AND THEIR METHADONE DOSE INCREASEDAS REQUIRED TO ALLEVIATE WITHDRAWAL SYMPTOMS.']